C-Reactive Protein and Cardiovascular Risk in the General Population: A European Heart Journal Study by Berkan Kurt et al.
Berkan Kurt, Resident Physician in Cardiology and Internal Medicine at Uniklinik RWTH Aachen, posted on LinkedIn:
“Deeply grateful to share that our article “C-reactive protein and cardiovascular risk in the general population” has now been published in the European Heart Journal.
In 448 653 adults without known ASCVD, a single hsCRP measurement showed strong stability over time, displayed long-term inflammatory risk, and independently predicted MACE, CV death and all-cause mortality across clinically relevant subgroups, including SMuRF-less but inflamed individuals. hsCRP ranked among the strongest predictors of CV outcomes and added incremental value to SCORE2-based risk prediction. 
Our findings underscore residual inflammatory risk as an additional, relevant dimension in primary prevention. Routine hsCRP assessment should be considered for inclusion in future guidelines to refine CV risk assessment and to improve prevention strategies in patients without a history of ASCVD.
Sincerely thankful to my mentor Florian Kahles for his continuous support and guidance, my colleague Martin Reugels for the outstanding work together on this project, and to all co-authors and international colleagues for their generous collaboration and the privilege of working together with leading experts in the field.
Open access article”
Title: C-reactive protein and cardiovascular risk in the general population
Authors: Berkan Kurt, Martin Reugels, Kai M Schneider, Jens Spiesshoefer, Andrea Milzi, Alexander Gombert, Christopher B Fordyce, Florian A Wenzl, Neha J Pagidipati, Viviane Rocha, Marat Fudim, Abhinav Sharma, Michael Lehrke, Hiroaki Shimokawa, Giovanna Liuzzo, Lale Tokgozoglu, Filippo Crea, Thomas F Lüscher, Peter Libby, Paul M Ridker, Nikolaus Marx, Carolin V Schneider, Florian Kahles

Get the latest from Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering